Abstract "Anxiety disorders" are extremely common; and are a major source of health costs and lost work days. Their diagnosis is currently based on clinical symptom check lists and there are no biological markers to diagnose speci c syndromal causes. This paper describes: 1) a detailed theory of the brain systems controlling anxiolytic-insensitive threat-avoidance and anxiolytic-sensitive threat-approach -where, in specific brain structures, activity generates specific normal behaviours, hyperactivity generates abnormal behaviours, and hyper-reactivity (hypersensitivity to input) generates specific clinical syndromes; 2) a rodent model of systemic anxiolytic action (rhythmical slow activity), linked to the theory, that over a period of 40 years has shown predictive validity with no false positives or false negatives -and which is likely to assay the sensitivity of endogenous systems that control anxiety; and, 3) derivation from this rodent-based theory of a specific non-invasive biomarker (goal-conflict-specific rhythmicity) for the threat-approach system in humans. This new biomarker should allow division of untreated "anxiety" patients, with superficially similar clusters of symptoms, into distinct high scoring (syndromal) and low scoring groups with different treatment-responses. This would be the first theoretically-derived biomarker for any mental disorder and should: 1) predict treatment efficacy better than current symptom-based diagnoses; 2) provide a human single dose test of novel anxiolytics; 3) provide a starting point for developing biomarkers for other "anxiety" syndromes; and so, 4) greatly improve treatment outcomes and cost-effectiveness.
The need for an anxiety syndrome biomarker A cluster of defensive pathologies, usually referred to as "anxiety disorders", afflict as much as 15% of the population in any one year [1] .
Diagnosis currently cannot identify syndromes
and so treatments are applied with poor predictive success, which increases costs and societal impact. While the focus of this paper is on anxiety disorders, it should be noted that similar problems with diagnosis occur with mental disorders generally. Work days lost to mental disorders as a whole are about double those lost to other health issues [1] . "Patients with mental disorders deserve better" [2] . This paper describes a rodent-based neuropsychology for which Rhythmical Slow Activity (RSA; "theta rhythm") is a key functional substrate and the derivation from this of a human biomarker, Goal Conflict-Specific Rhythmicity (GCSR). GCSR should, for the first time identify a specific, theoretically-derived (bottom up), neurallybased syndrome within the 'anxiety disorders' .
The paper does not attempt to review current attempts to derive psychiatric biomarkers using a top-down approach. It became immediately clear that [RDoC] cannot design a system based on biomarkers … because we lack the data." [2] Disorders of defensive reactions (often grouped as "anxiety disorders" [3] ) are currently assigned many speci c diagnoses within two main systems: The WHO International 
The problem of de ning anxiety
The difference in treatment of the fear/anxiety distinction in the two classi cation systems is not surprising given the variation in the normal uses of the words "fear" and "anxiety".
For some people fear is unconditioned and [5] , this question still has no consensus answer. Our unique approach [6] is to de ne "an emotion" as a set of reactions that share a common teleonomy [7] (i.e. evolutionary "purpose"/ adaptive function). The common usages that we considered above see fear and anxiety as almost synonyms. In contrast, while seeing both fear and anxiety as defensive reactions, we [8] link fear to withdrawal from threat and anxiety to the opposite, approach to threat. That is we define fear as the set of all those behavioural, Thus any neural or behavioural measure that is affected similarly by both a benzodiazepine and buspirone should be linked to "anxiety" as defined pharmacologically. Importantly, these drugs are likely to be acting on receptors that are normally modulated by endogenous compounds [9] [10] [11] The theory's fundamental axiom [42, 43] is that anxiolytic drugs act on, and so define, the Behavioural Inhibition System (BIS; the "anxiety" system). Anxiolytics are defined here as drugs acting at benzodiazepine or 5HT 1A receptors, which as a class can improve some cases of anxiety disorders but do not necessarily improve panic, phobia, depression or obsession [34] . The BIS is activated by approachavoidance conflict [8, 22] . It gets its name from its initial inhibition of on-going behaviour prior to replacing it with, e.g., risk assessment behaviour. Its outputs also include increased arousal, attention and negative emotional bias.
Anxiolytics, as a class, do not affect the Fight, Flight, Freeze System (FFFS; the "fear" system), which is sensitive to panicolytics such as fluoxetine. Most of the pharmacology that has characterised the BIS uses learning experiments [22, 43] ; but the same pharmacological separation occurs with innate responses [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] and is matched by functional (ethological) separation of these into "fear-"
and "anxiety-"related behaviours [46, 47, 57] . Table 1 . Clinical profile of drugs used to treat defensive disorders. Note that no drug has a specific effect on a single type of disorder but that benzodiazepines (classical, GABA-A agonists) and buspirone (novel, 5HT-1A agonist) share only an effect on generalised anxiety disorder (GAD). OCD = obsessive compulsive disorder. Adapted from [12] .
We attribute these separations to polar opposition on a dimension of "defensive direction": defensive withdrawal versus defensive approach [22, 36] . The same functional analysis [46, 47] de ned a second dimension of "defensive distance" (essentially perceived immediacy of threat), along which speci c functional behaviours are hierarchically organised [46, 47] ; leading to the suggestion that their neural control systems are also hierarchically organised [58] . We [8, 22] distilled these and other data on functional and dysfunctional defensive behaviour into the 2D theory ( Figure 1 ). This 2D theory of the control of defensive states is also the basis of the Reinforcement Sensitivity Theory of human personality [59] .
Normality, morbidity and comorbidity
Each of the modules (Figure 1 ) in the hierarchies of the BIS and FFFS can be involved primarily or secondarily in mental disorder. Activity within any speci c module will produce speci c behavioural and autonomic output; but can do so for a range of different reasons. With a strong threat (e.g. a close encounter with a grizzly bear on a narrow track) and a normal module (e.g.
periaqueductal grey, Figure 1 ) there will be normal output (e.g. heart rate increase, freezing, thoughts of death; i.e. normal, adaptive, panic).
With a weak threat and a hyper-reactive module there will be maladaptive, syndromal, output (e.g. panic resulting from hyper-reactivity of the periaqueductal grey [60] [61] [62] ). With no apparent threat, panic could also occur unexpectedly as a result of spontaneous periaqueductal grey activity [63] , such as epileptiform discharge, producing spontaneous panic [64] .
An important complication for clinical diagnosis is that with normal external input, and a normal module, symptomatic output can nonetheless occur as a result of abnormality in another module. Activity in any module impacts immediately on others through extensive reciprocal excitatory and inhibitory neural connections ( Figure 1) . Excitatory connections allow a threat detected by only one level of the hierarchy to engage modules higher and lower in the hierarchy to increase the probability of an appropriate response being generated at that point in time, or in the future via conditioning.
Inhibitory connections determine which level of the hierarchy is in immediate control of responding -for example, if avoidance is possible then undirected escape needs to be inhibited.
On a longer time scale, modules can become co-activated as a result of environmental feedback and learning. For example, panic -in the FFFS -can later result in anxiety [65] via activation of the BIS by conditioned stimuli (such as the place in which spontaneous panic first occurred), particularly in neurotic individuals. So, patients presenting with, for example, symptoms of panic and anxiety may have primary panic disorder with consequential anxiety [66] , primary anxiety disorder with increased arousal generating consequential panic [67] [68] [69] , or a combination of these problems. There are also conditions under which reduced anxiety releases panic from inhibition [58] . The same general scenarios will apply to all modules of both systems. Hyper-reactivity [70] of a module will generate a syndrome [8] , produce specific primary symptoms; and activate other modules, producing secondary symptoms [71] . As a result, symptoms will not be a good guide to syndromes.
The 2D theory predicts [8, 22] not only multiple distinct syndromes (Figure 1 ) but also explicitly allows comorbidities. Hyper-reactivity [72, 73] of (or spontaneous discharges in [63] ) the ventro-lateral periaqueductal grey would produce a "pure panic disorder" that would be approximately equivalent to the current diagnosis of "irritable heart syndrome" [64] . Genuine co-morbidity (as opposed to a mixture of primary and secondary symptoms) would occur when more than one module (or more than one system-wide modulatory input) is dysfunctionally hyper-reactive.
Rhythmical Slow Activity (RSA, theta) as a potential anxiety syndrome biomarker
Despite the apparent complexity of the relation between symptoms and syndromes, syndromes should be distinguishable by biomarkers. A key assumption of the 2D theory is that distinct disorders will represent hyperreactivity of distinct modules within a system or of inputs that modulate multiple modules of a system. That is, no symptoms need be shown currently; but a particular level of stimulus input to that module, delivered as a challenge, will produce greater than normal output. Panic, for example, can be provoked by a variety of physical challenges (CO 2 , lactate, etc.). Patients currently diagnosed with "panic disorder" and "irritable heart syndrome" often show a lower threshold (i.e. hyper-reactivity) to these challenges than do controls. However, with panic, there is as yet no strong theoretical link between the nature of the challenge and the cause of the underlying disorder [66] . What is required, therefore, are biomarkers for activity in speci c modules of the defense systems and for the modulating systems that control the global sensitivities of the BIS and/or FFFS.
We have developed the first such biomarker based on the fact [16, 22, 76, 77] that the BIS depends on Rhythmical Slow Activity (RSA; 4-12 Hz rhythmic cell firing -often referred to as "theta" despite its wide frequency range).
We have repeatedly shown [77] [78] [79] [80] [81] [82] [83] [84] [85] with intracranial EEG in rats that RSA frequency reduction, measured in the hippocampus, predicts clinical "anxiolytic" action (see [86] for review), with no false positives (even with sedatives) or negatives (even with drugs ineffective in panic or depression).
The predictive value of our rat test has been confirmed by others [87] [88] [89] [90] . We also proved that arti cial replacement of blocked RSA repairs behavioural dysfunction [91] (the first proof that any EEG rhythmicity is functional in and of itself ); and that changes in RSA mediate the action of anxiolytics on behavioural inhibition in an approach-avoidance conflict [92] . Thus RSA appears to be not just a reliable model of anxiolytic action but to be a significant neural substrate of an anxietyrelated process.
A human homologue of RSA
We developed a human homologue of rat RSA as a biomarker for BIS hyper-reactivity.
Hippocampal depth recording is impractical
for assessing anxiety disorders in humans.
However, in rats, rhythmicity in frontal cortex becomes coherent (phase-locked) with hippocampal RSA during risk assessment behaviours [93] . Since the hippocampus itself shows RSA even when it is not in control of behaviour, this outflow of RSA to prefrontal cortex should be more predictive of BIS functional output and act as a better biomarker than hippocampal recording. We therefore searched for rhythmicity in human frontal cortex that was generated by goal (approachavoidance) conflict and sensitive to anxiolytic drugs.
We measured human scalp EEG during approach, conflict, and avoidance, subtracting the average power in approach and avoidance from conflict to measure goal con ict-speci c rhythmicity (GCSR). We found GCSR at a right frontal cortex site (F8) [94, 95] . Right frontal cortex (particularly the inferior frontal gyrus) controls stopping [96] [97] [98] [99] (a major output of the BIS) in the Stop Signal Task (SST) [100] .
The SST is extremely simple to administer and has already been used with clinical cases such as ADHD and schizophrenia [101] . We used the SST to extract GCSR from F8 and found that this correlated positively with both trait anxiety and neuroticism [102] . Critically, we later showed that F8 GCSR was reduced by both benzodiazepine and 5HT 1A drugs [103] that share, in the clinic, only BIS and not FFFS or antidepressant actions. So, right frontal GCSR elicited in the SST task in humans is pharmacologically homologous to RSA elicited by electrical stimulation in rats.
Goal-con ict-speci c rhythmicity as a basis for an anxiety syndrome
Dysfunctional control of GCSR may support a specific BIS syndrome. In the clinic, anxiolytics can take weeks to achieve their full therapeutic effects. Even the benzodiazepines (which have immediate, but temporary, euphoriant and muscle relaxant effects) need time for their full core anxiolytic effects [104, 105] . In normal rats, acute administration of anxiolytics is e ective if anxiety is an immediately elicited state or being learned [43, 106] ; and both in animal RSA [86] and in human GCSR [103] , all anxiolytics are e ective immediately; with no change in this e ect over chronic administration [107] . Elicitation of GCSR, then, assesses the output from a mechanism, the chronic hyperreactivity of which could both predispose to and perpetuate clinical anxiety by modulating (stippled 5HT 1A /BDZ/RSA zone in Figure 1 ) the entire BIS.
GCSR provoked by the SST's approachavoidance challenge should identify BIS hyperreactivity. As noted above, GCSR amplitude correlates both with neuroticism (a general risk factor for multiple disorders [108] ) and trait anxiety (a more focussed measure of the chronic tendency to be "anxious" [109] ).
Importantly, the SST involves no threats and stopping behaviour itself does not correlate with neuroticism or trait anxiety and is not affected by benzodiazepine or 5HT 1A drugs [103] . The strength of elicited GCSR in the SST, thus measures the reactivity of a BIS circuit, un-confounded by concurrent challenges to the panic system or by changes in behaviour controlled by act and action circuits [102] that operate in parallel to each other and to goal control by the BIS (Figure 2 ).
An improved goal-con ictspeci c signal -homology with RSA
While satisfactory from a theoretical standpoint, our reported SST results [102, 103] have some limitations in relation to clinical translation. They involved a novel method of analysis that separated trials into three groups to allow application of a quadratic contrast [110] to extract conflict-specific rhythmicity. [37, 112, 113] .
Importantly, we also have unpublished data
showing that, as with the original SST [102, 103] , this GCSR is sensitive to buspirone (5HT 1A ) and triazolam (a short-acting benzodiazepine).
Buspirone and benzodiazepines are both clinically anxiolytic [104, 105] but use completely independent neural systems to affect RSA [80] . Buspirone is neither panicolytic [74] (unlike other antidepressant drugs) nor anticonvulsant, euphoriant, muscle relaxant or addictive (unlike benzodiazepines) [104, 114] .
We also found that GCSR was sensitive to pregabalin (a calcium channel inhibitor), which is positive in our rodent RSA test [90] , effective in generalised anxiety disorder [115] , and has not been reported to be clinically either primarily by the preSMA [99] With somewhat slower go responses stopping is controlled primarily by rIFG [97, 98] but BIS output is too slow to affect stopping in the SST [102] .With even slower go responses (as in go/no go tasks) activation of the BIS would generate response inhibition via rIFG/preSMA. avPFC = anteroventral prefrontal cortex; preSMA = presupplementary motor area; rIFG = right inferior frontal gyrus. From [102] . (unpublished data pooled from 3 separate experiments). GCSR was calculated as the difference in stopsignal speci c Fourier transform power between groups of trials with a stop signal delay that results in stop and go being in balanced conflict (50% of trials each) with the average power for groups where go or stop predominated. A positive value indicates an increase in rhythmic power specific to the presence of goal conflict. In this new version of the SST, power is increased in both the conventional theta (4-7 Hz) and conventional alpha (8-12 Hz) bands and so has a range that is very similar to the frequency range of the rodent RSA from which the test is theoretically derived.
of participants as a result of artefact, and may have insufficiently low error variance. However, our drug data show that it has the capacity to distinguish groups with N of the order of 10 and so it can be used as an anchor for the development of more clinically convenient instruments. We are currently starting a study to test this in anxiety disorder patients. 
GCSR as a test for novel anxiolytic compounds

GCSR as a test for syndromal anxiety and comorbidity
Importantly, GCSR should, for the first time, allow identification of a neurally distinct, syndromal, subgroup of "anxiety disorder" simple depression, being more chronic and severe, with higher suicide risk [117, 118] .
Only biomarkers can determine if this is the case. In addition, use of biomarkers would allow distinctions to be made between true comorbidity, where there is more than one locus of dysfunction, and cases where a primary morbidity (e.g. "spontaneous panic/ irritable heart syndrome") gives rise through either neural or societal links to secondary symptoms (e.g. "agoraphobia") that are also typical of some other primary morbidity ("pure agoraphobia").
Conclusion
In summary, GCSR is a non-invasive human measure that, like the rodent RSA model is 
